Ohio State Navbar


Manisha Shah, MBBS

Current OSU Appointments

  • Professor, Internal Medicine
  • Director, Neuroendocrine Tumor Clinic Program


Education and Training

  • M.B.B.S., Smt. N.H.l. Municipal Medical College
  • Internal Medicine Residency, Sheth K. M. School of Post Graduate Medicine and Research
  • Internal Medicine Residency, Buffalo General Hospital
  • Medical Oncology Fellowship, Roswell Park Cancer Institute
  • Medical Oncology Fellowship, The Ohio State University

Dr. Shah earned her MD degree from Gujarat University in India and completed her residency in Internal Medicine at the State University of New York at Buffalo. Dr. Shah then pursued two years of further training in Medical Oncology at the Roswell Park Cancer Institute, NY and one year of post-doctoral fellowship in the laboratory of Dr. Michael Caligiuri at OSU. Dr. Shah began her productive career focusing on innate immunity basic research as well as clinical care and research for patients with AIDS malignancies.  As opportunity came, Dr. Shah performed high quality and most original work on Endocrine related cancers since 1999.  She has been instrumental in building world-class multidisciplinary programs in neuroendocrine tumors (NET), thyroid and adrenocortical cancers.  Dr. Shah has led and developed innovative clinical trials with a goal to discover effective therapies for such rare cancers for which otherwise no standard treatment was available.  Dr. Shah’s clinical research has direct impact on improving lives of current and future generations of patients with rare cancers.  Dr. Shah has leadership role in various committees of numerous national and international organizations related to Thyroid cancers and Neuroendocrine Cancers.  Dr. Shah has successfully obtained ongoing independent funding since 2002 from National Comprehensive Cancer Network (NCCN), National Cancer Institute (NCI) or pharmas.

Dr. Shah was the first to embark on testing targeted therapies in patients with advanced differentiated (DTC)- and medullary (MTC)- thyroid cancer.  Based on effectiveness of sorafenib, a multikinase inhibitor, reported in her investigator-initiated NCI-sponsored phase II trials, sorafenib is now recommended by NCCN panel for patients with iodine-refractory DTC or metastatic MTC [J Clin Oncol, 2009 and 2010].  Furthermore, she was intimately involved in the conduct of two international phase III clinical trials testing experimental drug versus placebo in patients with gastrointestinal stromal tumors (GIST) [Lancet, 2006] or for pancreatic NET (pNET) [N Engl J Med, 2011].  As a result of these pivotal trials, we now have a first line standard of care therapy for patients with imatinib-refractory GIST and progressive advanced pNET. 

In recognition of her contributions, Dr. Shah has received numerous awards, including "Best Doctor in America" list and "Business first-forty under 40" Columbus, Ohio.  Dr. Shah regularly serves as a chair or co-chair of major scientific sessions or is an invited speaker at the extremely prestigious organizations, such as International Thyroid Congress, World Thyroid Congress, American Thyroid Association, North American Neuroendocrine Tumor Society, American Association for Cancer Research and National Cancer Institute.  Furthermore, Dr. Shan is a dedicated educator; she has routinely mentored trainees and junior faculty and involved them in writing grants, original or review manuscripts as well as book chapters. Dr. Shah has published in the journals with exceedingly high impact factors including Cancer Cell, Journal of Clinical Investigation, Journal of Clinical Oncology, Journal of Immunology, Lancet, Nature Medicine, New England Journal of Medicine, and Oncogene.